Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of intangible assets

Other operating expense (income), net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Quest Diagnostics

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Quest Diagnostics reports robust 2022 performance amidst COVID-19 testing decline

Quest Diagnostics delivered strong financial performance in 2022, with revenue growth and strategic acquisitions driving expansion.
Challenges include the anticipated decline in COVID-19 testing revenues and regional healthcare recovery disparities post-pandemic.
Opportunities lie in advanced diagnostics investments, productivity enhancements, and upcoming investor day to showcase growth strategies.
Overall, Quest Diagnostics remains focused on long-term growth, margin improvement, and shareholder value creation.

Quest Diagnostics reports strong Q1 earnings, eyes growth opportunities

Quest Diagnostics' Q1 performance reflects robust revenue growth and strategic acquisitions positioning the company for future success. Challenges in margin progression and market expectations for MRD testing require attention, while opportunities in oncology distribution and consumer testing optimization offer avenues for growth.

Quest Diagnostics reports robust Q2 earnings, raises guidance amid challenges

Quest Diagnostics demonstrated strong financial performance in Q2 2023, with revenue growth, margin improvement, and raised guidance, despite challenges like high turnover and labor costs.
The company's strategic focus on innovation, acquisitions, and pricing strategies presents opportunities for sustained growth and market expansion in clinical areas like genomics and oncology.
Navigating challenges related to employee turnover and cost pressures while leveraging opportunities in M&A, value-based care, and technological advancements will be crucial for Quest Diagnostics' future success.

Quest Diagnostics reports robust Q3 earnings amidst COVID challenges

Quest Diagnostics delivered strong financial results in Q3, showcasing growth in base business and adjusted EPS. While facing challenges from COVID-19 testing revenue decline and regulatory uncertainties, the company remains focused on leveraging opportunities in growth investments and margin improvements.

Quest Diagnostics reports robust 2023 performance and optimistic 2024 outlook

Quest Diagnostics delivered strong financial performance in 2023, with revenue growth driven by acquisitions and strategic initiatives.
The company's focus on oncology, Alzheimer's offerings, and AI tools deployment positions them for continued growth and innovation.
While facing short-term challenges like regulatory uncertainties and pricing pressures, Quest Diagnostics remains confident in their long-term outlook and growth prospects.
With a positive guidance for 2024, including revenue and EPS expectations, the company aims to navigate headwinds and capitalize on opportunities for sustainable growth.

Quest Diagnostics reports robust Q1 results and strategic growth plans

Quest Diagnostics' Q1 performance showcased strong revenue growth and strategic investments in advanced diagnostics and automation.
While facing challenges like regulatory concerns and pricing pressures, the company's focus on acquisitions and operational efficiency drives growth.
Opportunities lie in continued automation efforts, market expansion in advanced diagnostics, and the positive outlook for key acquisitions.
Overall, Quest Diagnostics' solid financial results and raised guidance reflect a resilient business poised for future growth.

Quest Diagnostics reports robust Q2 earnings amid strategic acquisitions

Quest Diagnostics' Q2 2024 performance reflects solid revenue growth, operational efficiency, and strategic acquisitions driving expansion.
Despite challenges related to acquisition impact on EPS and industry dynamics, Quest's strong balance sheet and growth strategy position it well for the future.
The company's focus on advanced diagnostics, financial stability, and market opportunities underscores its resilience and growth potential in the healthcare sector.

Quest Diagnostics reports strong Q3 growth driven by acquisitions and advanced diagnostics

Quest Diagnostics' Q3 2024 performance reflects a robust growth trajectory driven by strategic acquisitions and a focus on advanced diagnostics.
While facing integration challenges and market uncertainties, the company's strong revenue streams and operational initiatives position it well for future growth.
With a reaffirmed long-term outlook and proactive acquisition strategy, Quest Diagnostics remains poised for continued success in the healthcare diagnostics sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fourth quarter revenues of $2.33 billion, down 15.0% from 2021 Fourth quarter reported diluted earnings per share ("EPS") of $0.87, down 72.1% from 2021; and adjusted diluted EPS of $1.98, down 40.5% from 2021 Fourth quarter base business revenues of $2.15 billion, up 6.3% from 2021 Fourth quarter COVID-19 testing revenues of $184 million, down 74.6% from 2021 Full year revenues of $9.88 billion, down 8.4% from 2021 Full year reported diluted EPS of $7.97, down 48.7% from 2021; and adjusted diluted EPS of $9.95, down 30.1% from 2021 Full year base business revenues of $8.43 billion, up 5.1% from 2021 Full year COVID-19 testing revenues of $1.45 billion, down 47.5% from 2021 Full year 2023 reported diluted EPS expected to be between $7.61 and $8.21; and adjusted diluted EPS expected to be between $8.40 and $9.00 SECAUCUS, N.J. , Feb. 2, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2022.

QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2023

Quest Diagnostics Inc. DGX, +0.11% said Thursday its board has agreed to raise its quarterly dividend by 7.6% to 71 cents a share. The new dividend will be payable April 24 to shareholders of record as of April 10.

Quest Diagnostics raises quarterly dividend by 7.6% to 71 cents a share, boosts share buyback by $1 billion

SECAUCUS, N.J., Feb. 2, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the Company's Board of Directors has authorized a 7.6% increase in its quarterly dividend from $0.66 to $0.71 per share.

Quest Diagnostics Increases Dividend 7.6% To $0.71 Per Quarter; Announces $1 Billion Increase in Share Repurchase Authorization

SECAUCUS, N.J. , Feb. 1, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2023 for the ninth consecutive year.

FORTUNE Magazine Names Quest Diagnostics one of 2023 "World's Most Admired Companies" for Ninth Consecutive Year

Becton, Dickinson and Co.

CONMED

Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how BDX, DGX and CNMD are likely to fare this time.

MedTech Stocks' Earnings to Watch on Feb 2: BDX, DGX & CNMD

Analog Devices

Archer-Daniels-Midland Company

Allegion

Air Products and Chemicals

Apogee Enterprises

Avista

Booz Allen Hamilton Hld

Blackrock Inc

Church & Dwight

Cincinnati Financial

Cisco Systems

Chevron

California Water Service Group

Enterprise Bancorp

Con Ed

Eversource Energy

Exponent

Fastenal

Franklin Electric

Corning

Genuine Parts

Jack Henry & Associates

Kimberly-Clark

There is a slew of dividend increases coming in February, including from dividend kings Genuine Parts, 3M, and PepsiCo in the first half of the month. Other popular stocks that traditionally announce annual increases in early February are Sherwin-Williams and Cisco.

3 Dividend Kings Among 22 Companies To Announce Annual Dividend Increases In First Half Of February

Quest Diagnostics (DGX) ramps up investments to accelerate growth in the base business, particularly in advanced diagnostics and direct-to-consumer testing.

Quest Diagnostics (DGX) to Report Q4 Earnings: What's in Store?

Quest Launches the First Annual "Know Your Health" Survey to  Inspire Americans to Take Control of Their Well-being in 2023 SECAUCUS, N.J. , Jan. 23, 2023 /PRNewswire/ -- The consumer-initiated testing business from the leader in diagnostic testing, Quest Diagnostics (NYSE: DGX), today revealed the results of the first annual "Know Your Health" survey.

More Americans Know Their Horoscope Sign Than Their Blood Type, Survey Reveals

Agilent Technologies

SANTA CLARA, Calif.--( BUSINESS WIRE )--Agilent Technologies Inc. (NYSE: A) today announced an agreement with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. The alliance will enable providers and patients throughout the United States to access the Agilent Resolution ctDx FIRST liquid biopsy next-generation sequencing (NGS) test. Healthcare providers can order the test beginning today.

Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test

SECAUCUS, N.J. , Jan. 20, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2022 financial results on Thursday, February 2, 2023, before the market opens.

Quest Diagnostics to Release Fourth Quarter and Full Year 2022 Financial Results on February 2, 2023

Marks 1-Year since Quest Diagnostics Announced Plans to Acquire Pack Health to Extend Digital Engagement and Coaching Services to Health Plans, Employers and Life Sciences Companies BIRMINGHAM, Ala., Jan. 17, 2023 /PRNewswire/ -- Leading patient engagement company Pack Health, a Quest Diagnostics (NYSE: DGX) company, today announced plans to nearly double the space of its headquarter facilities in Birmingham and add at least 200 full-time employee positions based on economic development incentives from the state of Alabama in recognition of the public benefits accruing from the expansion of Pack Health's landmark Birmingham facility.

Pack Health to Expand in Birmingham to Accelerate Growth of Health Coaching Services Nationwide

AbbVie

Abbott Labs

Accenture Plc

Agree Realty

American Financial Group

American Financial Group Inc 6 1/4 % Debentures 2014-30.9.54 Subord

Air Lease

Alamo Group

Alerus Financial Corp

Amphenol

Algonquin Power & Utilities

Alexandria Real Estate Equities

Franklin Resources

Camden National

Community Bank System

City Hld

ConocoPhillips

Camden Property

CareTrust REIT

CubeSmart

Dollar General

Digital Realty Trust

Ecolab

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.

Dividend Champion, Contender, And Challenger Highlights: Week Of January 8

SECAUCUS, N.J. , Jan. 4, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 41st Annual J.P.

Quest Diagnostics to Speak at the 41st Annual J.P. Morgan Healthcare Conference

Investors are optimistic about Quest Diagnostics (DGX) on strong growth in the base business.

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

Analysis of 20 million clinical drug tests performed by Quest Diagnostics over the past decade shows increases in drug mixing and amphetamines use, and highlights the need for drug misuse prevention at the earliest stages of risk SECAUCUS, N.J. , Dec. 12, 2022 /PRNewswire/ -- Today, Quest Diagnostics (NYSE: DGX) released its latest Health Trends® report, "Drug Misuse in America 2022: A Decade Lost to the Drug Crisis.

One in Two Patients Tested Misuse Prescription Drugs, Finds 10th Annual Quest Diagnostics Health Trends® Report

Quest Diagnostics' (DGX) new collaboration with Northern Light Health will enhance access to diagnostics services in Maine.

Quest Diagnostics' (DGX) New Deal to Extend Laboratory Access

Quest to acquire Northern Light Health's outreach laboratory business and professionally manage nine of its hospital laboratories SECAUCUS, N.J. and BREWER, Maine , Dec. 8, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Northern Light Health, a large integrated healthcare system in Maine, today announced a strategic laboratory collaboration designed to broaden access to innovative, quality and cost-effective laboratory services powering affordable care for communities in Maine.

Quest Diagnostics and Northern Light Health Form Strategic Laboratory Collaboration to Improve Access to Affordable Diagnostic Services in Maine

Quest Diagnostics' (DGX) legacy base business is growing amid softer utilization trends.

Quest Diagnostics (DGX) Volume Growth Aids, Margin Woes Stay

Patient convenience improved by an easy-to-use scheduler for Getlabs in-home certified phlebotomy tests through Sonora Quest's website PHOENIX , Dec. 1, 2022 /PRNewswire/ -- Getlabs , the leader in providing nationwide infrastructure for remote health care delivery, and Sonora Quest Laboratories , Arizona's leading diagnostic testing laboratory, today announced that Getlabs' application programming interface (API) will be added to Sonora Quest's website. This integration allows patients to easily select and schedule an at-home sample collection when booking appointments through Sonora Quest's website, increasing the ease of access to vital health testing.

Sonora Quest Streamlines Access to At-Home Lab Services Through Getlabs Collaboration

Premier

SECAUCUS, N.J. , Dec. 1, 2022  /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, has been awarded a group purchasing agreement for its laboratory stewardship solution with Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company uniting an alliance of hospitals, health systems and providers.

Quest Diagnostics Awarded Laboratory Stewardship Platform and Services Agreement with Premier, Inc.

Physicians and patients to benefit from access to Quest's industry-leading test menu and broad health plan relationships in Northeastern Ohio SECAUCUS, N.J. and AKRON, Ohio , Nov. 28, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of select assets of LabCare Plus, the outreach laboratory services business of Summa Health, a large integrated health system.

Quest Diagnostics Completes Acquisition of Outreach Lab Services Business of Summa Health

Close to 400,000 uninsured and underinsured patients served by participating FQHCs in Texas, Maryland, Massachusetts, Florida, and Illinois can now receive specialty care eConsults, saving time and money for patients and providers and improving health outcomes for underserved patients. MIDDLETOWN, Conn.

ConferMED, through Grant from the Quest Diagnostics Foundation, now Providing Specialty eConsults to Front Line Primary Care Providers at Federally Qualified Health Centers in Five Key Metropolitan Areas

SECAUCUS, N.J. , Nov. 4, 2022 /PRNewswire/ --Quest Diagnostics (NYSE: DGX) has just unveiled three new fitness panels on questhealth.com, designed for athletes of every kind, from weekend warriors to gold medalists.

Quest Introduces First of Its Kind Fitness Tests Built By and For Athletes on questhealth.com

-  Former CEO Steve Rusckowski Remains as Chairman Through March 2023 SECAUCUS, N.J. , Nov. 1, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that Jim Davis has succeeded Steve Rusckowski as the CEO and President of Quest Diagnostics, completing a transition first announced on February 3, 2022.

Quest Diagnostics Completes Leadership Succession as Jim Davis Becomes CEO and President, Joins Board of Directors

One of the companies that benefitted hugely from the Covid-19 pandemic was diagnostic testing company Quest Diagnostics Inc ( DGX , Financial), which operates a national network of full-service clinical labs and over 2,200 patient service centers. That major tailwind has since subsided, and while there are still growth opportunities for clinical testing companies, the reduction in Covid-related income has made a wreck of the stock.

Quest Diagnostics Is a Wreck Amidst Covid-19 Testing Declines

News for Quest Diagnostics Stock (DGX)